Search
BioCryst Pharmaceuticals Inc
BCRXAdd to Watchlist
8.980USD
-0.260-2.81%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.28BMarket Cap
LossP/E TTM
More Details of BioCryst Pharmaceuticals Inc Company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
BioCryst Pharmaceuticals Inc Info
Ticker SymbolBCRX
Company nameBioCryst Pharmaceuticals Inc
IPO dateMar 04, 1994
CEOGayer (Charles K)
Number of employees580
Security typeOrdinary Share
Fiscal year-endMar 04
Address4505 Emperor Blvd Ste 200
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27703-8457
Phone19198591302
Websitehttps://www.biocryst.com/
Ticker SymbolBCRX
IPO dateMar 04, 1994
CEOGayer (Charles K)
Company Executives of BioCryst Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+1.45%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
364.62K
-109.37%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
268.70K
+45.29%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
147.98K
--
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
108.48K
+14.10%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+12.61%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
86.17K
+17.75%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
79.56K
+19.22%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
47.18K
+32.42%
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+1.45%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
364.62K
-109.37%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
268.70K
+45.29%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
147.98K
--
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
108.48K
+14.10%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+12.61%
FAQs
Who are the top five shareholders of BioCryst Pharmaceuticals Inc?
The top five shareholders of BioCryst Pharmaceuticals Inc are: Mr. Jon P. Stonehouse
How many institutions hold shares of BioCryst Pharmaceuticals Inc (BCRX)?
As of 2026Q1, 608 institutions hold shares of BioCryst Pharmaceuticals Inc, with a combined market value of approximately 235.68M, accounting for 92.73% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 6568788.00.